Examining clinical and genetic factors that impact response to anti-TNF agents in patients with IBD - Mayo Clinic
4.7
$ 7.50
In stock
(179)
Product Description
Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease - ScienceDirect
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease - Clinical Gastroenterology and Hepatology
(PDF) Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations
JCM, Free Full-Text
Frontiers Publishing Partnerships Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome
Intestinal Research
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Ulcerative colitis - The Lancet
Life, Free Full-Text
/cdn.vox-cdn.com/uploads/chorus_image/image/67728139/usa_today_15085635.0.jpg "Aaron Jones injury: Packers RB considered a game-time decision for Week 9 - DraftKings Network")
